Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Jun Liu, Yang Yang, Zhichao Liu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e004291-e004291
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer
Fan Ge, Zhenyu Huo, Xiuyu Cai, et al.
JAMA Network Open (2022) Vol. 5, Iss. 11, pp. e2239778-e2239778
Open Access | Times Cited: 70
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Zhichao Liu, Yaru Zhang, Ning Ma, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1852-1870.e9
Open Access | Times Cited: 54
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Jun Yin, Jingnan Yuan, Yunjin Li, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2068-2078
Open Access | Times Cited: 43
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Jianjun Qin, Liyan Xue, Anlin Hao, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2549-2557
Open Access | Times Cited: 40
Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
Yongkui Yu, Fanyu Meng, Xiufeng Wei, et al.
Journal of Thoracic and Cardiovascular Surgery (2024) Vol. 168, Iss. 2, pp. 417-428.e3
Closed Access | Times Cited: 19
Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 17
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
Man Wang, Fei Yu, Yuan Zhang
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 5
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Zhaoqing Tang, Yan Wang, Dan Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 63
Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease
Yun Li, Guanchao Jiang, Wendy Wu, et al.
EBioMedicine (2023) Vol. 91, pp. 104553-104553
Open Access | Times Cited: 30
Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
Baihua Zhang, Hongbo Zhao, Xun Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 23
Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
Yong Li, Aiping Zhou, Shuoyan Liu, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 22
Induction sintilimab and chemotherapy followed by concurrent chemoradiotherapy for locally advanced esophageal cancer: a proof-of-concept, single-arm, multicenter, phase 2 trial
Dashan Ai, Shengnan Hao, Wenbin Shen, et al.
EClinicalMedicine (2024) Vol. 69, pp. 102471-102471
Open Access | Times Cited: 14
Immunotherapy for esophageal cancer: Where are we now and where can we go
Yoshiaki Shoji, Kazuo Koyanagi, Kohei Kanamori, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 19, pp. 2496-2501
Open Access | Times Cited: 13
Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer
Xin Xu, Zhiyong Sun, Qiang Liu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 3, pp. e008631-e008631
Open Access | Times Cited: 12
Advancing Esophageal Cancer Treatment: Immunotherapy in Neoadjuvant and Adjuvant Settings
Daniel Park, Won Jin Jeon, Chieh Yang, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 318-318
Open Access | Times Cited: 10
Development of new techniques and clinical applications of liquid biopsy in lung cancer management
Kezhong Chen, Yue He, Wenxiang Wang, et al.
Science Bulletin (2024) Vol. 69, Iss. 10, pp. 1556-1568
Open Access | Times Cited: 9
The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma
Zheyi Wang, Yue Zhao, Yang Wo, et al.
Cancer Letters (2024) Vol. 593, pp. 216951-216951
Closed Access | Times Cited: 8
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
Mingxing Wang, Wanhui Dong, Gongyi Wu, et al.
Systematic Reviews (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma
Xufeng Guo, Chunji Chen, Jinbo Zhao, et al.
JAMA Surgery (2025)
Closed Access | Times Cited: 1
Patients with Upper Third of Esophageal Squamous Cell Carcinoma Have Better Tumor Regression After Neoadjuvant Immunochemotherapy
Yan He, Jun Yu, Tao Bao, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 1
Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
Zhi Zhang, Jinjun Ye, Hui Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 34
Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
Yujin Qiao, Cong Zhao, Xiangnan Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
Shaowu Jing, Chang Zhai, Wei Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 29
Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
Yunsong Liu, Yongxing Bao, Xu Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Advances in targeted therapy and immunotherapy for esophageal cancer
Haiou Yang, Xuewei Li, Wenhui Yang
Chinese Medical Journal (2023) Vol. 136, Iss. 16, pp. 1910-1922
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top